Artia Global Partners LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001937964

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 48 positions · Total reported value $541.86M · Top-10 concentration 64.5% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 30.4% · 7 new · 2 cut · 8 exited

Active Share (vs S&P 500): 98.5% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +16.1% · vs SPY +1.3% · Prev Value $396.61M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Artia Global Partners LP disclosed 48 equity positions with a combined reported value of $541.86M. The filing implies a focused portfolio: its ten largest positions account for 64.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ABVX ($68.82M), INSM ($62.80M), TRVI ($41.23M). By sector, the heaviest allocations are Health Care 94.9%, Industrials 2.0%. Versus the prior quarter, allocation shifted toward Other (+0.8pp).

Versus the prior quarter, Artia Global Partners LP opened 7 new positions, trimmed 2 and fully exited 8, a turnover rate of 30.4% of positions. The portfolio's overlap with the prior quarter was 73% of names.

The largest new positions opened in Q2 2026 were ALKS ($23.52M), XBI ($15.82M), GH ($5.72M).

Of the 8 positions fully exited versus the prior quarter, the largest were LLY ($35.15M), MRNA ($10.16M), TERN ($5.53M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ALKS ALKERMES PLC · $23.52M
  • XBI STATE STREET SPDR S&P BIOTECH ETF · $15.82M
  • GH GUARDANT HEALTH INC COM · $5.72M
  • ABSI ABSCI CORP · $5.38M
  • ORKA ORUKA THERAPEUTICS INC · $3.18M
  • CMPX COMPASS THERAPEUTICS INC · $839.21K
  • SYRE SPYRE THERAPEUTICS INC · $355.12K

Fully Exited (vs previous quarter)

  • LLY ELI LILLY · prev qtr: $35.15M
  • MRNA MODERNA INC COM · prev qtr: $10.16M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $5.53M
  • ABBV ABBVIE INC · prev qtr: $3.15M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $2.29M
  • BBIO BRIDGEBIO PHARMA INC · prev qtr: $1.51M
  • APGE APOGEE THERAPEUTICS INC · prev qtr: $495.43K
  • AVTX AVALO THERAPEUTICS INC · prev qtr: $432.52K

Insider Transactions (Form 4)

Latest Artia Global Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Artia Global Partners LP is an SEC-registered 13F filer based in Miami, FL, United States. As of Q2 2026 it reported 48 US equity positions with a combined value of $541.86M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: MIAMI, FL, United States
  • SEC registration: 801-125942 (status: Approved), registered 2022-06-23
  • Regulatory AUM (Form ADV): $778.89M as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 48 positions · $541.86M reported value (Q2 2026)
  • Top 10 holdings = 64.5% of reported value
  • Largest position: ABVX (ABIVAX SA) at 12.7%
  • Average position size: $11.29M

Sector Tilt

  • Health Care 94.9%
  • Industrials 2.0%
  • (classified holdings cover 97% of value)

Quarterly Activity

  • Q2 2026: 7 new, 11 added, 2 reduced, 8 exited
  • 28 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The Artia Global Partners LP fund seems to be adopting a conservative approach with a slight tilt towards growth in the healthcare sector. The addition of new positions in healthcare companies suggests a belief in the potential of this sector, while the reduction in ABIVAX SA (ABVX) indicates a cautious stance on specific healthcare stocks. 2. Key Moves: - Added: The fund added significant positions in INSMED INC (INSM), TREVI THERAPEUTICS INC (TRVI), BRIGHTSPRING HEALTH SVCS INC (BTSG), and REVOLUTION MEDICINES INC (RVMD). These additions reflect a focus on growth within the healthcare sector. - Reduced: The fund reduced its position in ABIVAX SA (ABVX), by 14.0% from the previous quarter. - New: ALKERMES PLC (ALKS) was a new addition to the portfolio. 3. Portfolio Structure: - Passive/Active: The rebalancing suggests a slightly active management approach, as the fund is actively adding and reducing positions within the portfolio. - Sector Bias: The fund has a strong bias towards the healthcare sector, which is reflected in the top-10 holdings. - Risk Appetite: The addition of several growth-oriented healthcare stocks indicates a moderate to high risk appetite, balanced with the reduction in ABVX, a cautious approach. 4. Per-Holding One-Liner: - ABVX: ABIVAX SA, a biotechnology company focused on developing therapies for orphan diseases. unverified - INSM: INSMED INC, a biopharmaceutical company focused on developing treatments for rare diseases. unverified - TRVI: TREVI THERAPEUTICS INC, a biopharmaceutical company specializing in rare genetic disorders. unverified - BTSG: BRIGHTSPRING HEALTH SVCS INC, a healthcare services company offering home healthcare services. unverified - RVMD: REVOLUTION MEDICINES INC, a biotechnology company focusing on cancer therapies. unverified - ARGX: ARGENX SE, a biopharmaceutical company focused on developing therapies for immune disorders. unverified - ALKS: ALKERMES PLC, a biopharmaceutical company focused on developing therapies for central nervous system and metabolic disorders. unverified - TVTX: TRAVERE THERAPEUTICS INC, a biotechnology company developing therapies for cancer. unverified - AZN: ASTRAZENECA PLC, a pharmaceutical company specializing in treatments for various diseases, including cancer. unverified - NAMS: NEWAMSTERDAM PHARMA COMPANY, a biopharmaceutical company focused on developing treatments for neurological diseases. unverified 5. One-Sentence Style Summary: Artia Global Partners LP rebalanced its portfolio in Q2 2026 by increasing exposure to growth-oriented healthcare stocks and maintaining a cautious approach with selective reductions, indicating a slightly active and sector-focused strategy.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 94.9%
Other 3.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 516.45K $68.82M 12.70%
12.70%
Reduce
2 589.05K $62.80M 11.59%
11.59%
Add
3 2.21M $41.23M 7.61%
7.61%
Add
4 517.32K $36.08M 6.66%
6.66%
Add
5 185.39K $34.72M 6.41%
6.41%
Add
6 29.74K $27.59M 5.09%
5.09%
Hold
7 448.96K $23.52M 4.34%
4.34%
New
8 339.03K $19.26M 3.56%
3.56%
Add
9 98.38K $18.65M 3.44%
3.44%
Add
10 503.94K $17.08M 3.15%
3.15%
Hold
11 162.99K $15.89M 2.93%
2.93%
Hold
12 100.00K $15.82M 2.92%
2.92%
New
13 65.12K $13.80M 2.55%
2.55%
Add
14 144.38K $11.45M 2.11%
2.11%
Hold
15 767.10K $10.97M 2.02%
2.02%
Hold
16 278.55K $7.84M 1.45%
1.45%
Reduce
17 180.73K $7.05M 1.30%
1.30%
Hold
18 59.32K $6.21M 1.15%
1.15%
Add
19 70.70K $6.02M 1.11%
1.11%
Add
20 46.70K $6.00M 1.11%
1.11%
Hold
21 138.51K $5.77M 1.06%
1.06%
Hold
22 22.60K $5.74M 1.06%
1.06%
Hold
23 38.10K $5.72M 1.05%
1.05%
New
24 464.44K $5.38M 0.99%
0.99%
New
25 96.28K $5.30M 0.98%
0.98%
Hold
26 119.74K $5.27M 0.97%
0.97%
Hold
27 17.74K $4.73M 0.87%
0.87%
Hold
28 129.80K $4.59M 0.85%
0.85%
Hold
29 1.99M $4.16M 0.77%
0.77%
Hold
30 98.80K $4.01M 0.74%
0.74%
Add
31 18.44K $3.98M 0.73%
0.73%
Hold
32 65.00K $3.92M 0.72%
0.72%
Hold
33 24.99K $3.85M 0.71%
0.71%
Hold
34 137.80K $3.72M 0.69%
0.69%
Hold
35 1.81M $3.69M 0.68%
0.68%
Hold
36 72.10K $3.66M 0.68%
0.68%
Add
37 33.40K $3.18M 0.59%
0.59%
New
38 22.95K $2.81M 0.52%
0.52%
Hold
39 5.00K $2.71M 0.50%
0.50%
Hold
40 38.41K $2.70M 0.50%
0.50%
Hold
41 29.20K $1.87M 0.34%
0.34%
Hold
42 383.20K $839.21K 0.15%
0.15%
New
43 2.50K $836.98K 0.15%
0.15%
Hold
44 17.02K $663.06K 0.12%
0.12%
Hold
45 42.08K $612.26K 0.11%
0.11%
Hold
46 4.90K $605.15K 0.11%
0.11%
Hold
47 205.32K $369.58K 0.07%
0.07%
Hold
48 4.00K $355.12K 0.07%
0.07%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 70% R 70% F1 70% (modelled on 2026-Q1; 7/10 hit)

Low-confidence forecast This fund replaces about 36% of its Top-10 each quarter and backtests at F1 64% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 64% · recall 64% · F1 64% · avg rank error 3.4 · Top-10 turnover 36%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 90% 90% 90% NVO · MRK · LLY · ABBV · AZN · ARGX · VKTX · AXSM · NBIX · ITCI NVO · LLY · MRK · VKTX · ABBV · ITCI · ARGX · AZN · VRTX · AXSM
2024-Q2 80% 80% 80% NVO · LLY · MRK · VKTX · ABBV · ITCI · VRTX · ARGX · AZN · OCUL LLY · MRK · NVO · AZN · ITCI · VRTX · ALNY · VKTX · AXSM · ARGX
2024-Q3 80% 80% 80% LLY · MRK · NVO · ITCI · AZN · ALNY · VRTX · VKTX · AXSM · PCVX NVO · VKTX · ITCI · AZN · SLNO · LLY · ALNY · VRTX · PCVX · ARGX
2024-Q4 50% 50% 50% NVO · VKTX · ITCI · SLNO · AZN · LLY · ALNY · PCVX · VRTX · AXSM SLNO · MRUS · ITCI · ACLX · NUVL · PCVX · ALNY · AZN · RVMD · VRNA
2025-Q1 50% 50% 50% SLNO · MRUS · ITCI · NUVL · ACLX · PCVX · RVMD · ALNY · INSM · VRNA LLY · VRNA · ITCI · INSM · MRUS · PTGX · ACLX · AZN · BSX · DGX
2025-Q2 60% 60% 60% LLY · VRNA · ITCI · INSM · MRUS · PTGX · ACLX · AZN · BSX · DGX ARGX · SLNO · LLY · BSX · MRUS · DGX · AZN · VRNA · XBI · TRVI
2025-Q3 50% 50% 50% ARGX · SLNO · LLY · BSX · DGX · MRUS · AZN · VRNA · XBI · TRVI ARGX · INSM · SLNO · VRNA · QURE · MRUS · UGL · LLY · VRTX · ABVX
2025-Q4 50% 50% 50% ARGX · INSM · SLNO · VRNA · QURE · UGL · MRUS · VRTX · LLY · TRVI INSM · ARGX · LLY · VKTX · TRVI · QURE · NAMS · AZN · CDTX · EYPT
2026-Q1 60% 60% 60% INSM · LLY · ARGX · VKTX · QURE · TRVI · NAMS · AZN · EYPT · CDTX ABVX · INSM · LLY · TRVI · ARGX · AZN · NAMS · DNTH · RVMD · IONS
2026-Q2 ★ 70% 70% 70% ABVX · INSM · LLY · TRVI · ARGX · NAMS · AZN · DNTH · RVMD · IONS ABVX · INSM · TRVI · BTSG · RVMD · ARGX · ALKS · TVTX · AZN · NAMS

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Artia Global Partners LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Artia Global Partners LP reported 48 equity positions worth $541.86M in aggregate; its largest disclosed positions were ABVX ($68.82M), INSM ($62.80M), TRVI ($41.23M).

How large is Artia Global Partners LP's portfolio?

Artia Global Partners LP reported $541.86M of long equity holdings across 48 positions as of 2026-Q2. Top-10 holdings account for 64.5% of reported value.

What is Artia Global Partners LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/artia-global-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →